Last reviewed · How we verify
IBI112
IBI112 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
IBI112 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Other solid tumors (in development).
At a glance
| Generic name | IBI112 |
|---|---|
| Sponsor | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IBI112 is a humanized monoclonal antibody targeting programmed death receptor 1 (PD-1). By blocking PD-1, the drug prevents tumor cells from suppressing T cell-mediated immunity, allowing the immune system to recognize and attack cancer cells more effectively. This mechanism is similar to other checkpoint inhibitors and is designed to enhance endogenous anti-tumor immunity across multiple cancer types.
Approved indications
- Non-small cell lung cancer
- Gastric cancer
- Other solid tumors (in development)
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
Key clinical trials
- A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis (PHASE2)
- IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment (PHASE3)
- A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics (PHASE2)
- A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis (PHASE2)
- Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI112 CI brief — competitive landscape report
- IBI112 updates RSS · CI watch RSS
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. portfolio CI